Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence
Gene expression-based recurrence assays are strongly recommended to guide the use of chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing is expensive, can contribute to delays in care, and may not be available in low-resource settings. Here, we describe the training and independent validation of a deep learning model that predicts recurrence assay result and risk of recurrence using both digital histology and clinical risk factors. We demonstrate that this approach outperforms an established clinical nomogram (area under the receiver operating characteristic curve of 0.833 versus 0.765 in an external validation cohort, p = 0.003), and can identify a subset of patients with excellent prognoses who may not need further genomic testing.